 BiondVax Pharmaceuticals Ltd. Nasdaq: BVXV announced today that preliminary data from the Phase 2 clinical trial of BiondVaxs M-001 universal influenza vaccine candidate have been published. The trial was supported by the U.S. National Institute of Allergy and Infectious Diseases NIAID, part of the National Institutes of Health NIH. The primary objectives of the trial were to assess safety and T-cell responses to M001. The data, which are consistent with results of previous clinical trials of M-001, indicate that both primary objectives were achieved. Analysis of the data is ongoing, and the clinical study report CSR is expected in Q2 2020. 